Developments in the treatment of juvenile arthritis
Although rarely a life-threatening disease, juvenile arthritis (JA) can, if poorly controlled, profoundly affect growth, development and quality of life in children. Long-term damage in children with JA rarely arises from overly aggressive therapy, but rather from an overly conservative and cautious...
Gespeichert in:
| Veröffentlicht in: | Expert opinion on pharmacotherapy 2004-07, Vol.5 (7), p.1485-1496 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1496 |
|---|---|
| container_issue | 7 |
| container_start_page | 1485 |
| container_title | Expert opinion on pharmacotherapy |
| container_volume | 5 |
| creator | Reiff, Andreas Otto |
| description | Although rarely a life-threatening disease, juvenile arthritis (JA) can, if poorly controlled, profoundly affect growth, development and quality of life in children. Long-term damage in children with JA rarely arises from overly aggressive therapy, but rather from an overly conservative and cautious approach in the early stages of the disease. As more potential therapeutic agents for JA become available, the physician must become skilled in viewing the data with a critical eye with regard to safety and efficacy in the paediatric population. The following review discusses the prognosis and management of JA, with a focus on new emerging agents for the treatment of this disease. |
| doi_str_mv | 10.1517/14656566.5.7.1485 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_15212599</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66641989</sourcerecordid><originalsourceid>FETCH-LOGICAL-c402t-c9ac419784dd305d828e42aec7242114343a8a25aad9f55c4a794587748e0b543</originalsourceid><addsrcrecordid>eNp9kD9PwzAQxS0EoqXwAVhQJraU2LFjR7Cg8leqxAKzdXUuaqokLrZT1G-PqxYhFnSD7-zfezo_Qi5pNqWCyhvKCxGrmIqpnFKuxBEZU8l5KouiOI59fE93wIiceb_KMpaVgp-SERWMMlGWY5I_4AZbu-6wDz5p-iQsMQkOIexuElsnq2GDfdNiAi4sXRMaf05Oamg9XhzOCfl4enyfvaTzt-fX2f08NTxjITUlGE5LqXhV5ZmoFFPIGaCRjDNKec5zUMAEQFXWQhgOsuRCSckVZgvB8wm53vuunf0c0AfdNd5g20KPdvA6fjL6qzKCdA8aZ713WOu1azpwW00zvUtK_ySlhd4NSkTN1cF8WHRY_SoO0UTgbg80fW1dB1_WtZUOsG2tqx30pvE6_8__9o98idCGpQGHemUH18fg_tnuGxe6iTA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66641989</pqid></control><display><type>article</type><title>Developments in the treatment of juvenile arthritis</title><source>Taylor & Francis</source><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><creator>Reiff, Andreas Otto</creator><creatorcontrib>Reiff, Andreas Otto</creatorcontrib><description>Although rarely a life-threatening disease, juvenile arthritis (JA) can, if poorly controlled, profoundly affect growth, development and quality of life in children. Long-term damage in children with JA rarely arises from overly aggressive therapy, but rather from an overly conservative and cautious approach in the early stages of the disease. As more potential therapeutic agents for JA become available, the physician must become skilled in viewing the data with a critical eye with regard to safety and efficacy in the paediatric population. The following review discusses the prognosis and management of JA, with a focus on new emerging agents for the treatment of this disease.</description><identifier>ISSN: 1465-6566</identifier><identifier>EISSN: 1744-7666</identifier><identifier>DOI: 10.1517/14656566.5.7.1485</identifier><identifier>PMID: 15212599</identifier><language>eng</language><publisher>England: Ashley Publications Ltd</publisher><subject>Arthritis, Juvenile - classification ; Arthritis, Juvenile - diagnosis ; Arthritis, Juvenile - drug therapy ; Double-Blind Method ; Humans ; juvenile arthritis ; Multicenter Studies as Topic ; Prognosis ; Randomized Controlled Trials as Topic ; Technology, Pharmaceutical - trends ; treatment ; Treatment Outcome</subject><ispartof>Expert opinion on pharmacotherapy, 2004-07, Vol.5 (7), p.1485-1496</ispartof><rights>2004 Ashley Publications Ltd 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c402t-c9ac419784dd305d828e42aec7242114343a8a25aad9f55c4a794587748e0b543</citedby><cites>FETCH-LOGICAL-c402t-c9ac419784dd305d828e42aec7242114343a8a25aad9f55c4a794587748e0b543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1517/14656566.5.7.1485$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1517/14656566.5.7.1485$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,59620,59726,60409,60515,61194,61229,61375,61410</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15212599$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reiff, Andreas Otto</creatorcontrib><title>Developments in the treatment of juvenile arthritis</title><title>Expert opinion on pharmacotherapy</title><addtitle>Expert Opin Pharmacother</addtitle><description>Although rarely a life-threatening disease, juvenile arthritis (JA) can, if poorly controlled, profoundly affect growth, development and quality of life in children. Long-term damage in children with JA rarely arises from overly aggressive therapy, but rather from an overly conservative and cautious approach in the early stages of the disease. As more potential therapeutic agents for JA become available, the physician must become skilled in viewing the data with a critical eye with regard to safety and efficacy in the paediatric population. The following review discusses the prognosis and management of JA, with a focus on new emerging agents for the treatment of this disease.</description><subject>Arthritis, Juvenile - classification</subject><subject>Arthritis, Juvenile - diagnosis</subject><subject>Arthritis, Juvenile - drug therapy</subject><subject>Double-Blind Method</subject><subject>Humans</subject><subject>juvenile arthritis</subject><subject>Multicenter Studies as Topic</subject><subject>Prognosis</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Technology, Pharmaceutical - trends</subject><subject>treatment</subject><subject>Treatment Outcome</subject><issn>1465-6566</issn><issn>1744-7666</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kD9PwzAQxS0EoqXwAVhQJraU2LFjR7Cg8leqxAKzdXUuaqokLrZT1G-PqxYhFnSD7-zfezo_Qi5pNqWCyhvKCxGrmIqpnFKuxBEZU8l5KouiOI59fE93wIiceb_KMpaVgp-SERWMMlGWY5I_4AZbu-6wDz5p-iQsMQkOIexuElsnq2GDfdNiAi4sXRMaf05Oamg9XhzOCfl4enyfvaTzt-fX2f08NTxjITUlGE5LqXhV5ZmoFFPIGaCRjDNKec5zUMAEQFXWQhgOsuRCSckVZgvB8wm53vuunf0c0AfdNd5g20KPdvA6fjL6qzKCdA8aZ713WOu1azpwW00zvUtK_ySlhd4NSkTN1cF8WHRY_SoO0UTgbg80fW1dB1_WtZUOsG2tqx30pvE6_8__9o98idCGpQGHemUH18fg_tnuGxe6iTA</recordid><startdate>20040701</startdate><enddate>20040701</enddate><creator>Reiff, Andreas Otto</creator><general>Ashley Publications Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040701</creationdate><title>Developments in the treatment of juvenile arthritis</title><author>Reiff, Andreas Otto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c402t-c9ac419784dd305d828e42aec7242114343a8a25aad9f55c4a794587748e0b543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Arthritis, Juvenile - classification</topic><topic>Arthritis, Juvenile - diagnosis</topic><topic>Arthritis, Juvenile - drug therapy</topic><topic>Double-Blind Method</topic><topic>Humans</topic><topic>juvenile arthritis</topic><topic>Multicenter Studies as Topic</topic><topic>Prognosis</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Technology, Pharmaceutical - trends</topic><topic>treatment</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reiff, Andreas Otto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Expert opinion on pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reiff, Andreas Otto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Developments in the treatment of juvenile arthritis</atitle><jtitle>Expert opinion on pharmacotherapy</jtitle><addtitle>Expert Opin Pharmacother</addtitle><date>2004-07-01</date><risdate>2004</risdate><volume>5</volume><issue>7</issue><spage>1485</spage><epage>1496</epage><pages>1485-1496</pages><issn>1465-6566</issn><eissn>1744-7666</eissn><abstract>Although rarely a life-threatening disease, juvenile arthritis (JA) can, if poorly controlled, profoundly affect growth, development and quality of life in children. Long-term damage in children with JA rarely arises from overly aggressive therapy, but rather from an overly conservative and cautious approach in the early stages of the disease. As more potential therapeutic agents for JA become available, the physician must become skilled in viewing the data with a critical eye with regard to safety and efficacy in the paediatric population. The following review discusses the prognosis and management of JA, with a focus on new emerging agents for the treatment of this disease.</abstract><cop>England</cop><pub>Ashley Publications Ltd</pub><pmid>15212599</pmid><doi>10.1517/14656566.5.7.1485</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1465-6566 |
| ispartof | Expert opinion on pharmacotherapy, 2004-07, Vol.5 (7), p.1485-1496 |
| issn | 1465-6566 1744-7666 |
| language | eng |
| recordid | cdi_pubmed_primary_15212599 |
| source | Taylor & Francis; MEDLINE; Taylor & Francis Medical Library - CRKN |
| subjects | Arthritis, Juvenile - classification Arthritis, Juvenile - diagnosis Arthritis, Juvenile - drug therapy Double-Blind Method Humans juvenile arthritis Multicenter Studies as Topic Prognosis Randomized Controlled Trials as Topic Technology, Pharmaceutical - trends treatment Treatment Outcome |
| title | Developments in the treatment of juvenile arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T01%3A48%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Developments%20in%20the%20treatment%20of%20juvenile%20arthritis&rft.jtitle=Expert%20opinion%20on%20pharmacotherapy&rft.au=Reiff,%20Andreas%20Otto&rft.date=2004-07-01&rft.volume=5&rft.issue=7&rft.spage=1485&rft.epage=1496&rft.pages=1485-1496&rft.issn=1465-6566&rft.eissn=1744-7666&rft_id=info:doi/10.1517/14656566.5.7.1485&rft_dat=%3Cproquest_pubme%3E66641989%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66641989&rft_id=info:pmid/15212599&rfr_iscdi=true |